Marker Therapeutics, Inc.

Tagged: phase 2 trial

TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials

TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.

Read More